Skip to main navigation Skip to search Skip to main content

Prolyl-isomerase Pin1 drives platinum resistance by regulating Notch3 stability and function in ovarian cancer

Maria Valeria Giuli, Angelica Mancusi, Bianca Natiello, Samuele Di Cristofano, Rebecca Reali, Maria Gemma Pignataro, Daniel D’Andrea, Laura Di Magno, Carmine Nicoletti, Alessandra Giorgi, Alberto Macone, Serena Camerini, Marialuisa Casella, Giovanna Peruzzi, Sabrina Zema, Gianluca Canettieri, Federica Tomao, Innocenza Palaia, Angelina Pernazza, Alessandra RustighiRocco Palermo, Domenico Raimondo, Alessandra Monti, Nunzianna Doti, Giulia d’Amati, Giannino Del Sal, Isabella Screpanti, Claudio Talora*, Diana Bellavia, Saula Checquolo*

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)peer-review

Abstract

Background:
Resistance to platinum-based drugs represents a major obstacle for the management of high-grade serous ovarian cancer (HGSOC) patients. Indeed, the selective pressure of platinum-based (PT) chemotherapy often leads to the outgrowth of platinum-resistant subclones. In this scenario, the underlying adaptive networks should be fully investigated to provide advances toward more streamlined and personalized care.

Methods:
We conducted a comprehensive analysis of Pin1/Notch3relationship from HGSOC cell lines and primary tumours, integrating multiple genetic targeting under chemotherapy pressure, differential proteomic approaches, molecular docking data and dynamics simulations, thus identifying a functional circuit evaluated in vitro and in vivo models.We conducted a comprehensive analysis of relationship from HGSOC cell lines and primary tumours, integrating multiple genetic targeting under chemotherapy pressure, differential proteomic approaches, molecular docking data and dynamics simulations, thus identifying a functional circuit evaluated in vitro and in vivo models.

Results:
Here, we demonstrated that carboplatin treatment of HGSOC cells promoted the activation of the Pin1/Notch3 axis, resulting in platinum resistance. Accordingly, HGSOC-bearing patients showing increased Pin1/Notch3 co-expression after PT-based chemotherapy correlated with a clinical worse response. Conversely, genetic targeting of Pin1 combined with carboplatin treatment sensitizes resistant cells to platinum-based therapy, both in vitro and in vivo, strongly reducing their Notch3-mediated metastatic potential in preclinical murine models. Mechanistically, Pin1-Notch3 binding favours protection of Notch3 from its GSK3β-mediated degradation, resulting in increased Notch3 expression.

Conclusions:
Collectively, our findings identify the functional Pin1/Notch3 axis as an escape strategy from chemotherapy-induced cell death, thus suggesting a novel predictive role of the Pin1/Notch3 axis in the platinum response, which could be useful for implementing frontline treatments for HGSOC patients before recurrence.
Original languageEnglish
Article number71
Number of pages22
JournalJournal of Experimental & Clinical Cancer Research
Volume45
Issue number1
DOIs
Publication statusPublished - 11 Feb 2026

Bibliographical note

Publisher Copyright:
© The Author(s) 2026.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Platinum drug resistance
  • HGSOC
  • Pin1 targeting
  • Notch3

Fingerprint

Dive into the research topics of 'Prolyl-isomerase Pin1 drives platinum resistance by regulating Notch3 stability and function in ovarian cancer'. Together they form a unique fingerprint.

Cite this